🟡 Preliminary Evidence
Most people who take melatonin supplements approach them as a simple replacement—when melatonin is low, take melatonin. But your body naturally synthesises melatonin every night through a multi-step biochemical pathway that depends critically on micronutrient cofactors including iron, folate, B6, zinc, and magnesium. Without these raw materials, even supplementation may not restore normal sleep architecture.
Key takeaways
- Melatonin synthesis requires four enzymatic steps, each dependent on specific micronutrient cofactors: iron, folate, B6, zinc, magnesium, and methylation substrates
- Endogenous melatonin production declines by approximately 50% during puberty and falls to 10–20% of childhood levels by age 70, driven by pineal gland calcification
- The Nurses’ Health Study (n=998) found no significant association between dietary nutrient intake and urinary melatonin metabolites, suggesting nutrients are necessary but not sufficient
- The physiological dose of melatonin is approximately 0.3 mg; typical over-the-counter supplements provide 3–10 mg—10–33 times higher than the dose shown to restore sleep efficiency in older adults
Melatonin Synthesis Pathway and Cofactor Requirements
Four enzymatic steps from tryptophan to melatonin, each requiring specific micronutrients
Source: Biochemical pathway synthesis | Georgian Medical Journal News
The Four-Step Synthesis Pathway and Its Cofactor Bottlenecks
Melatonin is synthesised from the amino acid tryptophan through four sequential enzymatic reactions. The first enzyme, tryptophan hydroxylase, requires iron and folate to convert tryptophan to 5-hydroxytryptophan (5-HTP). The second step, catalysed by aromatic amino acid decarboxylase, depends on vitamin B6 to produce serotonin. The third step, catalysed by serotonin N-acetyltransferase (SNAT), requires zinc and magnesium and activates only in darkness—a critical circadian mechanism. The fourth and final step, a methylation reaction catalysed by hydroxyindole O-methyltransferase (HIOMT), depends on S-adenosylmethionine (SAM), itself synthesised from folate, vitamin B12, and methionine.
This interdependence means that deficiency in any single cofactor—iron, B6, magnesium, zinc, or folate—will slow or stall the pathway at that point, with cascading effects on all downstream steps. See our explainers section for more on micronutrient biochemistry.
Age-Related Decline: The Pineal Gland and the 70-Year-Old Problem
Endogenous melatonin production is not constant across the lifespan. Melatonin levels peak in early childhood (ages 1–5), then decline approximately 50% through puberty, and continue falling to approximately 10–20% of childhood levels by age 70. This decline is driven by two age-related processes: pineal gland calcification—the gradual accumulation of calcium phosphate in pineal tissue—and reduced neural signaling to the gland over time. By the seventh decade of life, the gland’s synthetic capacity is substantially compromised, independent of cofactor availability.
This explains why melatonin supplementation is often prescribed for older adults with insomnia. However, the mechanism is not simply replacement of a missing hormone; it may involve restoring circadian phase alignment and sleep architecture through exogenous ligand binding to melatonin receptors, a separate process from endogenous synthesis.
The Evidence Gap: Nutrients Are Necessary But Not Sufficient
The pathway biochemistry and cofactor requirements are well established in biochemistry textbooks and peer-reviewed literature. However, direct evidence linking dietary micronutrient intake to melatonin production in humans is limited. The Nurses’ Health Study, a prospective cohort of n=998 participants, found no significant association between intakes of tryptophan, folate, B6, zinc, or other examined nutrients and urinary melatonin metabolites. Light exposure remains the dominant regulator of melatonin synthesis; circadian timing, not nutrient status, drives the on-off switch for the pathway.
This does not mean cofactors are irrelevant. Rather, it suggests they are permissive factors—necessary for the pathway to run, but not predictive of final output in people with adequate micronutrient status. In populations with frank deficiency (severe iron deficiency anaemia, B12 deficiency, etc.), cofactor repletion may improve endogenous production. But in adequately nourished populations, dietary optimisation is unlikely to substantially raise melatonin levels; light hygiene and circadian alignment remain first-line interventions.
The physiological dose of melatonin is approximately 0.3 mg. At this dose, sleep efficiency was restored in older adults with insomnia and plasma melatonin rose to normal levels. Typical over-the-counter supplements provide 3–10 mg—10–33 times higher—raising questions about appropriateness for age-specific dosing.
— Zhdanova research group, MIT Department of Brain and Cognitive Sciences
Melatonin Supplementation: Dosing Misalignment and Clinical Implications
Research from the Zhdanova laboratory at MIT demonstrated that the physiological dose of melatonin is approximately 0.3 mg. At this dose, sleep efficiency improved in older adults with insomnia and plasma melatonin concentrations rose to normal levels. Yet the vast majority of over-the-counter melatonin products contain 3 mg to 10 mg per tablet—10 to 33 times the physiological dose. This 30-fold dose escalation raises important questions: Does supraphysiological dosing improve efficacy, or does it merely increase receptor occupancy beyond physiological need? Are there age-stratified dosing recommendations, or are all adults given the same tablet?
Higher doses may suppress endogenous melatonin production through negative feedback (though evidence for this in humans is limited) and may increase the risk of next-day grogginess or other adverse effects. The evidence base for optimal dosing across age groups remains sparse. Visit our clinical updates for guidance on evidence-based sleep medicine approaches.
What this means
Frequently asked questions
Does taking a B-complex or multivitamin improve melatonin production?
In people with adequate micronutrient status, supplementation is unlikely to raise melatonin levels significantly, according to findings from the Nurses’ Health Study. However, if you have documented deficiencies in iron, B6, B12, or folate—identifiable through blood tests—repletion may restore pathway function. Discuss testing and supplementation with your clinician.
Why do melatonin supplements come in such high doses (3–10 mg) if 0.3 mg is physiological?
The reasons include market convention, lack of standardised dosing guidance, and the assumption that higher doses improve efficacy. However, dose-response studies suggest diminishing returns beyond physiological levels. Supraphysiological dosing may increase side effects (grogginess, vivid dreams) without proportional benefit. Low-dose formulations (0.3–1 mg) are becoming more available and are supported by evidence.
Is melatonin safe to take every night?
Melatonin is generally well tolerated in short-term use (weeks to months). Long-term safety data in humans are limited. Regular use may suppress endogenous production through negative feedback, though this is debated. If you need nightly melatonin, discuss duration and discontinuation strategies with your doctor. Consider combining it with light therapy and sleep hygiene optimisation to address root causes of circadian misalignment.
The melatonin supplement market has grown into a multi-billion-dollar industry by reframing a circadian hormone as a simple sleep aid and replacement therapy. But melatonin biology is more nuanced: endogenous production depends on cofactors, circadian timing, and pineal gland function; exogenous supplementation works through receptor activation, not nutrient repletion. Dosing is often misaligned with physiological need. A more evidence-based approach would distinguish between light-responsive circadian disorders (which benefit from melatonin and light therapy) and primary insomnia (which benefits from cognitive-behavioural therapy and sleep hygiene), and would offer age-appropriate, low-dose melatonin only when indicated. Until dosing guidelines are standardised and marketed products better align with physiological evidence, patients should approach melatonin supplementation as a tool for circadian synchronisation, not as a micronutrient replacement.
Source: Most people who take melatonin treat it like any other pill
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
